-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DCJFKz/oNHdeML0cRJqjrLskVVOBBfRxvHOoHeXC6zKtZN6KNWDoEHyyCKGrc4O+ SeI7fwIpynsoIrl9v1Cidg== 0000909012-01-000107.txt : 20010223 0000909012-01-000107.hdr.sgml : 20010223 ACCESSION NUMBER: 0000909012-01-000107 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010214 GROUP MEMBERS: FLEMING ROBERT INC / DA GROUP MEMBERS: FLEMING US DISCOVERY FUND III, LP GROUP MEMBERS: FLEMING US DISCOVERY OFFSHORE FUND III, LP GROUP MEMBERS: FLEMING US DISCOVERY PARTNERS LP GROUP MEMBERS: FLEMING US DISCOVERY, LLC GROUP MEMBERS: ROBERT FLEMING INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMPAX LABORATORIES INC CENTRAL INDEX KEY: 0001003642 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650403311 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-48867 FILM NUMBER: 1544895 BUSINESS ADDRESS: STREET 1: 30831 HAYWARD AVE CITY: HAYWARD STATE: CA ZIP: 94544 BUSINESS PHONE: 2152892220 MAIL ADDRESS: STREET 1: CASTOR & KENSINGTON AVENUES CITY: PHILADELPHIA STATE: PA ZIP: 19124-5694 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\ DATE OF NAME CHANGE: 19951117 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FLEMING ROBERT INC / DA CENTRAL INDEX KEY: 0000902812 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 320 PARK AVENUE STREET 2: 11TH & 12TH FL CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2125083600 MAIL ADDRESS: STREET 1: 320 PARK AVE STREET 2: 11TH AND 12TH FL CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: FLEMING ROBERT INC DATE OF NAME CHANGE: 19930429 SC 13D/A 1 0001.txt IMPAX LABORATORIES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ----------------- SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2(A) (Amendment No. 5)(1) IMPAX LABORATORIES, INC. (formerly GLOBAL PHARMACEUTIUCAL CORPORATION) - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $ .01 per share - ------------------------------------------------------------------------------- (Title of Class of Securities) 45256B101 - ------------------------------------------------------------------------------- (CUSIP Number) Larry A. Kimmel Robert Fleming Inc. 320 Park Avenue, 11th Floor New York, NY 10022 (212) 508-3610 - ------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 31, 2000 - ------------------------------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13D to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box |_|. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. SEE Rule 13d-7(b) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 12 Pages) - ---------- 1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, SEE the NOTES). CUSIP No. 45256B101 13D Page 2 of 12 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) FLEMING US DISCOVERY FUND III, L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) [X] (B) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES -------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER* OWNED BY EACH REPORTING 0 PERSON WITH -------------------------------------------------------------- 9 SOLE DISPOSITIVE POWER 0 -------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 -------------------------------------------------------------- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! -2- CUSIP No. 45256B101 13D Page 3 of 12 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) FLEMING US DISCOVERY OFFSHORE FUND III, L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) [X] (B) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION BERMUDA - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 0 REPORTING ------------------------------------------------------- PERSON WITH 9 SOLE DISPOSITIVE POWER 0 ------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 ------------------------------------------------------- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! -3- CUSIP No. 45256B101 13D Page 4 of 12 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) FLEMING US DISCOVERY PARTNERS, L.P. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A)[X]: (B) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 0 REPORTING ------------------------------------------------------- PERSON WITH 9 SOLE DISPOSITIVE POWER 0 ------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 ------------------------------------------------------- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* PN - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! -4- CUSIP No. 45256B101 13D Page 5 of 12 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) FLEMING US DISCOVERY, LLC - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) [X] (B) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 5,458,334 SHARES ------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 0 REPORTING ------------------------------------------------------- PERSON WITH 9 SOLE DISPOSITIVE POWER 5,458,334 ------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 ------------------------------------------------------- - ------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON SEE ITEM 5 OF ATTACHED SCHEDULE - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) SEE ITEM 5 OF ATTACHED SCHEDULE - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* OO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! -5- CUSIP No. 45256B101 13D Page 6 of 12 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) ROBERT FLEMING INC. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) [X] (B) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 833,300 SHARES --------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 0 REPORTING --------------------------------------------------------- PERSON WITH 9 SOLE DISPOSITIVE POWER 833,300 --------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 --------------------------------------------------------- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) SEE ITEM 5 OF ATTACHED SCHEDULE - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* IA, CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! -6- CUSIP No. 45256B101 13D Page 7 of 12 Pages 1 NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) J.P. MORGAN CHASE & CO. ("JPMC")* * JPMC disclaims any beneficial ownership of the shares of Impax Laboratories, Inc. reported as beneficially owned by any other Reporting Person. JPMC is named herein solely for informational purposes. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) (B) - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER 0 --------------------------------------------------------- NUMBER OF 8 SHARED VOTING POWER SHARES BENEFICIALLY 0 OWNED BY --------------------------------------------------------- EACH 9 SOLE DISPOSITIVE POWER REPORTING PERSON WITH 0 --------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* HC - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! -7- ITEM 1. SECURITY AND ISSUER This Amendment No. 5 to the Statement on Schedule 13D originally filed on March 12, 1999, as amended by Amendment No. 1 thereto filed on July 15, 1999, Amendment No. 2 thereto filed on December 27, 1999, Amendment No. 3 filed on May 12, 2000, Amendment No. 4 thereto filed on December 20, 2000 (as so amended, the "Statement") with respect to the common stock, $.01 par value per share (the "Common Stock"), of Impax Laboratories, Inc., a Delaware corporation (the "Issuer") amends and restates Items 2 and 5 and Appendices 1 and 2, and supplements Item 7. The address of the Issuer's principal executive offices is 30831 Huntwood Avenue, Haywood, California 94544. Information in the original Schedule 13D remains in effect except to the extent that it is superseded by subsequently filed information, including the information contained in this Amendment No. 5. Responses to each item below are incorporated by reference into each other item, as applicable. None of the Reporting Persons has made any additional purchases or sales of stock of the Issuer since the events described in Amendment No. 4 to Schedule 13D. This Amendment No. 5 relates to changes in the ownership structure of certain Fleming entities in connection with the acquisition of Robert Fleming Holdings Limited by The Chase Manhattan Corporation and the subsequent merger of J.P. Morgan & Co. Incorporated with and into The Chase Manhattan Corporation. Upon completion of the merger December 31, 2000, The Chase Manhattan Corporation changed its name to "J.P. Morgan Chase & Co." ITEM 2. IDENTITY AND BACKGROUND This Statement is being filed pursuant to a Joint Filing Agreement (attached as Exhibit 1 and incorporated herein by reference) by (i) Fleming US Discovery Fund III, L.P. ("US Fund"), (ii) Fleming US Discovery Offshore Fund III, L.P. ("Offshore Fund"), (iii) Fleming US Discovery Partners, L.P. ("Fleming Partners"), the general partner of the US Fund and a general partner of the Offshore Fund, (iv) Fleming US Discovery, LLC ("Discovery"), the general partner of Fleming Partners, (v) Robert Fleming Inc. ("RFI"), investment adviser to Fleming US Discovery Investment Trust and Fleming US Discovery Fund, controlling member of Discovery and the sole limited partner of Fleming Partners and (vi) J.P. Morgan Chase & Co. ("JPMC"), the parent of RFI (sometimes collectively referred to as the "Reporting Persons"). Robert Fleming Holdings Limited ("RFH"), a United Kingdom company and a reporting person on the filing of the original Schedule 13D and amendments thereto, is no longer a direct or indirect parent of any Reporting Person, and therefore, is no longer a Reporting Person for the purposes of this Statement. The information required by this Item for each of the Reporting Persons is set forth in Appendix 1 hereto. The information required by this Item for each officer, director, and partner and each controlling person, if any, of certain Reporting Persons is set forth in Appendix 2 hereto. The Offshore Fund has two general partners, Fleming Partners and Fleming (Bermuda) Discovery III Limited ("Fleming Bermuda"). Fleming Bermuda is a company organized in Bermuda. Its principal business and office address is c/o Bank of Bermuda, Ltd., 6 Front St., Hamilton HM 11, Bermuda. Its principal business is to serve as a general partner of the Offshore Fund. -8- During the last five years prior to the date of this filing, none of the Reporting Persons or persons identified in Appendix 1 or Appendix 2 has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction ending in a judgment, decree or final order enjoining future violations or prohibiting or mandating the activities subject to, federal or state securities laws or finding a violation with respect to such laws. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION - ------ ------------------------------------------------- Not applicable. ITEM 4. PURPOSES OF TRANSACTIONS - ------- ------------------------ No change. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER - ------- ------------------------------------ As of the date hereof, the US Fund holds (w) 718,167 shares of Common Stock; (x) 43,093 shares of Series 1-A Preferred Stock, which are convertible into 2,154,650 shares of Common Stock, subject to certain anti-dilution provisions (the "US Fund Series 1-A Conversion Shares"), (y) 64,637 shares of Series 2 Convertible Preferred Stock (the "US Fund Series 2 Preferred Stock"), which are convertible into 1,292,740 shares of Common Stock, subject to certain anti-dilution provisions (the "US Fund Series 2 Conversion Shares"), and (z) warrants to purchase up to 538,662 shares of Common Stock (the "US Fund Warrant Shares"). As of the date hereof, the Offshore Fund holds (w) 115,167 shares of Common Stock (the "Offshore Fund Common Stock"), (x) 6,907 shares of Series 1-A Preferred Stock, which are convertible into 345,350 shares of Common Stock, subject to certain anti-dilution provisions (the "Offshore Fund Series 1-A Conversion Shares"), (y) 10,363 shares of Series 2 Convertible Preferred Stock (the "Offshore Fund Series 2 Preferred Stock"), which are convertible into 207,260 shares of Common Stock, subject to certain anti-dilution provisions (the "Offshore Fund Series 2 Conversion Shares"), and (z) warrants to purchase up to 86,338 shares of Common Stock (the "Offshore Fund Warrant Shares"). As of the date hereof, Robert Fleming Nominees Limited, a partnership that holds, as nominee, securities of funds advised by RFI ("RF Nominees"), holds 833,300 shares of Common Stock (the "RF Nominees Common Stock"), which are owned by two funds, Fleming US Discovery Investment Trust and Fleming US Discovery Fund, for whom RFI serves as investment adviser. RF Nominees is owned 100% by RFH. -9- Because of their relationship as affiliated entities, for purposes of Rule 13d-3 promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), the US Fund and the Offshore Fund may be deemed to beneficially own the US Fund Common Stock, the US Fund Series 1-A Conversion Shares, the US Fund Series 2 Conversion Shares, the US Fund Warrant Shares, the Offshore Fund Common Stock, the Offshore Fund Series 1-A Conversion Shares, the Offshore Fund Series 2 Conversion Shares and the Offshore Fund Warrant Shares. As the general partner of the US Fund and the Offshore Fund, Fleming Partners may be deemed to beneficially own the US Fund Common Stock, the US Fund Series 1-A Conversion Shares, the US Fund Series 2 Conversion Shares, the US Fund Warrant Shares, the Offshore Fund Common Stock, the Offshore Fund Series 1-A Conversion Shares, the Offshore Fund Series 2 Conversion Shares and the Offshore Fund Warrant Shares. As the general partner of Fleming Partners, Discovery may be deemed to beneficially own the US Fund Common Stock, the US Fund Series 1-A Conversion Shares, the US Fund Series 2 Conversion Shares, the US Fund Warrant Shares, the Offshore Fund Common Stock, the Offshore Fund Series 1-A Conversion Shares, the Offshore Fund Series 2 Conversion Shares and the Offshore Fund Warrant Shares. As investment adviser to the two funds that own the RF Nominees Common Stock, controlling member of Discovery and the sole limited partner of Fleming Partners, for purposes of Rule 13d-3 promulgated under the Exchange Act, RFI may be deemed to beneficially own the US Fund Common Stock, the US Fund Series 1-A Conversion Shares, the US Fund Series 2 Conversion Shares, the US Fund Warrant Shares, the Offshore Fund Common Stock, the Offshore Fund Series 1-A Conversion Shares, the Offshore Fund Series 2 Conversion Shares, the Offshore Fund Warrant Shares and the RF Nominees Common Stock. RFI is 100% owned by JPMC. Thus, as the parent of RFI, for purposes of Rule 13d-3 promulgated under the Exchange Act, JPMC may be deemed to beneficially own the US Fund Common Stock, the US Fund Series 1-A Conversion Shares, the US Fund Series 2 Conversion Shares, the US Fund Warrant Shares, the Offshore Fund Common Stock, the Offshore Fund Series 1-A Conversion Shares, the Offshore Fund Series 2 Conversion Shares, the Offshore Fund Warrant Shares and the RF Nominees Common Stock. JPMC disclaims any beneficial ownership of the shares of the Issuer reported as beneficially owned by any other Reporting Person. JPMC is named herein solely for informational purposes. As of the date hereof, for purposes of Rule 13d-3 promulgated under the Exchange Act, each of the US Fund, the Offshore Fund, Fleming Partners, and Discovery may be deemed to have beneficially owned 16.7% of the outstanding Common Stock, on an aggregated basis, which percentage is calculated based upon (i) 28,052,317 (25,635,648 shares of Common Stock reported outstanding by the Issuer to the Reporting Persons as of October 25, 2000 and 2,416,669 shares issued pursuant to the Stock Purchase Agreements), (ii) the US Fund Common Stock and the Offshore Fund Common Stock (833,334), (iii) the number of shares of Common Stock (2,500,000) issuable upon conversion of the US Fund Series 1-A Preferred Stock and Offshore Fund Series 1-A Preferred Stock, (iv) the number of shares of Common Stock (1,500,000) issuable upon conversion of the US Fund Series 2 Preferred Stock and Offshore Fund Series 2 Preferred Stock and (v) the number of shares of Common Stock (625,000) issuable upon exercise of the US Fund Warrant Shares and the Offshore Fund Warrant Shares. The percentage is calculated by dividing 5,458,334 (which is the sum of 833,334, 2,500,000, 1,500,000 and 625,000) by 32,677,317 (which is the sum of 2,500,000, 1,500,000, 625,000, 25,635,648 and 2,416,669). -10- As of the date hereof, for purposes of Rule 13d-3 promulgated under the Exchange Act, each of RFI and JPMC may be deemed to have owned beneficially 19.25% of the outstanding Common Stock, on an aggregated basis, which percentage is calculated based upon upon (i) 28,052,317 (25,635,648 shares of Common Stock reported outstanding by the Issuer to the Reporting Persons as of October 25, 2000 and 2,416,669 shares issued pursuant to the Stock Purchase Agreements, (ii) the US Fund Common Stock and the Offshore Fund Common Stock (833,334), (iii) the number of shares of Common Stock (2,500,000) issuable upon conversion of the US Fund Series 1-A Preferred Stock and Offshore Fund Series 1-A Preferred Stock, (iv) the number of shares of Common Stock (1,500,000) issuable upon conversion of the US Fund Series 2 Preferred Stock and Offshore Fund Series 2 Preferred Stock, (v) the number of shares of Common Stock (625,000) issuable upon exercise of the US Fund Warrant Shares and the Offshore Fund Warrant Shares and (vi) the RFI Common Stock (833,300). The percentage is calculated by dividing 6,291,634 (which is the sum of 833,334, 2,500,000, 1,500,000, 625,000 and 833,300) by 32,677,317 (which is the sum of 2,500,000, 1,500,000, 625,000, 25,635,648 and 2,416,669). (b) The information required by this paragraph is reflected on Lines 7-10 of each Reporting Person's cover page, incorporated herein by reference. The information required by Items 2 of this Schedule for Fleming US Discovery Investment Trust and Fleming US Discovery Fund is set forth in Appendix 1 and Appendix 2 hereto. (c) None of the Reporting Persons has effected any transactions in the Common Stock during the last 60 days. (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons. (e) Not Applicable. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT - ------ --------------------------------------------------------------------- TO SECURITIES OF THE ISSUER ---------------------------- No change. ITEM 7. MATERIALS TO BE FILED AS EXHIBITS - ------- --------------------------------- The following additional material is filed as an Exhibit to this Amendment No. 5: Exhibit 1 - Joint Filing Agreement. Exhibit 2 - Limited Partnership Agreement of Fleming Discovery Offshore Fund III, L.P. (incorporated by reference to Exhibit 3 to the Schedule 13D of Robert Fleming Inc. with respect to the securities of Anicom, Inc. filed on July 29, 1997). -11- Exhibit 3 - Limited Partnership Agreement of Fleming US Discovery Fund III, L.P. (incorporated by reference to Exhibit 6 to the Schedule 13D of Robert Fleming Inc. with respect to the securities of Anicom, Inc. filed on July 29, 1997). Appendix 1- Address, Organization and Principal Business of Each Reporting Person Required by Item 2 Appendix 2- Information About Each Reporting Person Required by Item 2 -12- SIGNATURE After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct. Dated: February 14, 2001 FLEMING US DISCOVERY FUND III, L.P. By: Fleming US Discovery Partners, L.P., its general partner By: Fleming US Discovery, LLC, its general partner By: /S/ ROBERT L. BURR --------------------------------------- Robert L. Burr, Member FLEMING US DISCOVERY OFFSHORE FUND III, L.P. By: Fleming US Discovery Partners, L.P, its general partner By: Fleming US Discovery, LLC, its general partner By: /S/ ROBERT L. BURR -------------------------------------- Robert L. Burr, Member FLEMING US DISCOVERY PARTNERS, L.P. By: Fleming US Discovery, LLC, its general partner By: /S/ ROBERT L. BURR ------------------------------------ Robert L. Burr, Member FLEMING US DISCOVERY, LLC By: /S/ ROBERT L. BURR ------------------------------------ Robert L. Burr, Member ROBERT FLEMING INC. By: /S/ ARTHUR A. LEVY ------------------------------------- Arthur A. Levy, Director J.P. MORGAN CHASE & CO. By: /S/ SUSAN S. SPAGNOLA ----------------------------------- Susan S. Spagnola, Assistant Corporate Secretary -13- Exhibit 1 JOINT FILING AGREEMENT Pursuant to and in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree to jointly file the Schedule 13D/A dated February 14, 2001 and any amendments thereto with respect to the beneficial ownership by each of the undersigned of shares of common stock of Impax Laboratories, Inc. Such joint filings may be executed by one or more of us on behalf of each of the undersigned. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original. Dated: February 14, 2001 FLEMING US DISCOVERY FUND III, L.P. By: Fleming US Discovery Partners, L.P., its general partner By: Fleming US Discovery, LLC, its general partner By: /S/ ROBERT L. BURR ------------------------- Robert L. Burr, Member FLEMING US DISCOVERY OFFSHORE FUND III, L.P. By: Fleming US Discovery Partners, L.P, its general partner By: Fleming US Discovery, LLC, its general partner By: /S/ ROBERT L. BURR -------------------------- Robert L. Burr, Member FLEMING US DISCOVERY PARTNERS, L.P. By: Fleming US Discovery, LLC, its general partner By: /S/ ROBERT L. BURR -------------------------- Robert L. Burr, Member FLEMING US DISCOVERY, LLC By: /S/ ROBERT L. BURR ------------------------------- Robert L. Burr, Member ROBERT FLEMING INC. By: /S/ ARTHUR A. LEVY ------------------------------------ Arthur A. Levy, Director J.P. MORGAN CHASE & CO. By: /S/ SUSAN S. SPAGNOLA ------------------------------------ Susan S. Spagnola, Assistant Corporate Secretary -14- APPENDIX 1 ADDRESS, ORGANIZATION AND PRINCIPAL BUSINESS OF EACH REPORTING PERSON REQUIRED BY ITEM 2 AND OTHER PERSONS REQUIRED BY ITEM 5
PRINCIPAL BUSINESS AND OFFICE PLACE OF REPORTING PERSON ADDRESS ORGANIZATION PRINCIPAL BUSINESS - ---------------- ------- ------------ ------------------ FLEMING US DISCOVERY FUND 320 Park Avenue Delaware limited partnership to invest in securities with a view III, L.P. ("US FUND") 11th Floor to long-term capital appreciation New York, NY 10022 FLEMING US DISCOVERY c/o Bank of Bermuda, Ltd Bermuda limited partnership to invest in securities with a view OFFSHORE FUND III, L.P. 6 Front St to long-term capital appreciation ("OFFSHORE FUND," WITH US FUNDS THE Hamilton HM 11 Bermuda "FUNDS") FLEMING US DISCOVERY 320 Park Avenue, Delaware limited partnership to act as the general partner of PARTNERS, L.P. 11th Floor the Funds ("FLEMING PARTNERS") New York, NY 10022 FLEMING US DISCOVERY, LLC 320 Park Avenue, Delaware limited liability to act as the sole general partner 11th Floor companY of Fleming Partners New York, NY 10022 ROBERT FLEMING INC. 320 Park Avenue, Delaware corporation a registered investment adviser and 11th Floor broker-dealer New York, NY 10022 J.P. MORGAN CHASE & CO. 270 Park Avenue, Delaware corporation a parent holding company New York, N.Y. 10017 OTHER FLEMING US DISCOVERY Fleming Investment Trust United Kingdom Investment Trust an investment manager INVESTMENT TRUST Management Limited 10 Aldermanbury London EC2V 7RF FLEMING US DISCOVERY Fleming Fund Management A Societe Anonyme an investment manager FUND (Luxembourg) S.a r.l incorporated under the laws European Bank & Business Center of the Grand Duchy of 6 route de Treves Luxembourg L-2633 Senningerberg Grand-Duchy of Luxembourg
-15- Appendix 2 INFORMATION ABOUT REPORTING PERSONS REQUIRED BY ITEM 2 MANAGERS AND COMMITTEES OF FLEMING US DISCOVERY, LLC MANAGERS Robert Fleming Inc. Robert L. Burr Christopher M.V. Jones* Eytan M. Shapiro* Timothy R.V. Parton* EXECUTIVE COMMITTEE Arthur A. Levy Iain O.S. Saunders Jonathan K.L. Simon Robert L. Burr Christopher M.V. Jones INVESTMENT COMMITTEE Robert L. Burr Christopher M.V. Jones Eytan M. Shapiro Timothy R.V. Parton David J. Edwards* Robert M. Zech * Eytan M. Shapiro, Christopher M.V. Jones, Timothy R.V. Parton and David J. Edwards are United Kingdom citizens. Robert L. Burr and Robert M. Zech are United States citizens. Their business address is 320 Park Avenue, 11th Floor, New York, New York 10022. The citizenship and business address, for each of the remaining persons listed above is contained in "Executive Officers and Directors of Robert Fleming Inc." -16- EXECUTIVE OFFICERS AND DIRECTORS OF ROBERT FLEMING INC. Name: William Robert Maas Citizenship: United States Business Address: The Chase Manhattan Bank 270 Park Avenue New York, N.Y. 10017 Title: Director Name: Arthur A. Levy Citizenship: United States Business Address: Robert Fleming Inc. 320 Park Avenue New York, NY 10022 Title: Chairman and Director Name: Christopher M.V. Jones Citizenship: United Kingdom Business Address: Robert Fleming Inc. 320 Park Avenue New York, NY 10022 Title: Director Name: Larry A. Kimmel Citizenship: United States Business Address: Robert Fleming Inc. 320 Park Avenue New York, NY 10022 Title: President and Director Name: Jonathan K.L. Simon Citizenship: United Kingdom Business Address: Robert Fleming Inc. 320 Park Avenue New York, NY 10022 Title: Director Name: Leonard Lubrano Citizenship: United States Business Address: Robert Fleming Inc. 320 Park Avenue New York, NY 10022 Title: Chief Financial Officer and Senior Vice President Name: Charlie Bridge Citizenship: United Kingdom Business Address: Robert Fleming Securities 10 Aldermanbury London EC2V 7RF Title: Director Name: Eduardo Canet Citizenship: United States Business Address: Robert Fleming Inc. 320 Park Avenue New York, NY 10022 Title: Director *With the exception of William Maas and Charlie Bridge, the business address for each of the above persons is 320 Park Avenue, New York, N.Y. 10022. -18- J.P. MORGAN CHASE & CO. EXECUTIVE AND OTHER OFFICERS* Douglas A. Warner III Chairman of the Board, Co-Chair of the Executive Committee William B. Harrison Jr. President and CEO, Co-Chair of the Executive Committee Geoffrey T. Boisi Vice Chairman/Co-CEO of the investment bank David A. Coulter Vice Chairman/Head of the retail business; leads the new firm's Internet initiatives Ramon de Oliveira Managing Director/Head of asset management and wealth management business Walter A. Gubert Chairman of the investment bank; Chair of European region Thomas B. Ketchum Managing Director/Chair of Technology Council; Co-chair of the merger integration team Donald H. Layton Vice Chairman/Co-CEO of the investment bank James B. Lee Jr. Vice Chairman/Head of the investment bank's new business and commitments committees Marc J. Shapiro Vice Chairman/Head of finance, risk management, and administration; Co-chair of the merger integration team Jeffrey C. Walker Senior managing partner/Head of the private equity group Dina Dublon Chief Financial Officer John C. Farrell Director Human Resources Frederick W. Hill Director Corporate Marketing and Communications William H. McDavid General Counsel Peter Gleysteen Chief Credit Officer Leslie Daniels Webster Head Market Risk Management *Principal occupation is employee and/or officer of JPMC. Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York, New York 10017. **Each of the persons named below is a citizen of the United States of America, other than Walter A. Gubert, who is an Italian citizen. DIRECTORS** Hans W. Becherer Retired Chairman and Chief Executive Officer Deere & Co. One John Deere Place Moline, Illinois 61265 Riley P. Bechtel Chairman and Chief Executive Officer Bechtel Group, Inc. P.O. Box 193965 San Francisco, California 94119-3965 -19- Frank A. Bennack, Jr. President and Chief Executive Officer The Hearst Corporation 959 Eighth Avenue New York, New York 10019 Lawrence A. Bossidy Retired Chairman of the Board Honeywell International Inc. c/o J.P. Morgan Chase & Co. 270 Park Avenue New York, New York 10017-2070 M. Anthony Burns Chairman Ryder System, Inc. 3600 N.W. 82nd Avenue Miami, FL 33196 H. Laurance Fuller Retired Co-Chairman BP Amoco p.l.c. c/o J.P. Morgan Chase & Co. 270 Park Avenue New York, New York 10017-2070 Ellen V. Futter President and Trustee American Museum of Natural History Central Park West at 79th Street New York, New York 10024 William H. Gray, III President and Chief Executive Officer The College Fund/UNCF 9860 Willow Oaks Corporate Drive P.O. Box 10444 Fairfax, Virginia 22031 William B. Harrison, Jr. President and Chief Executive Officer J.P. Morgan Chase & Co. 270 Park Avenue New York, New York 10017-2070 Helene L. Kaplan Of Counsel Skadden, Arps, Slate, Meagher & Flom LLP Four Times Square New York, New York 10036 Lee R. Raymond Chairman of the Board and Chief Executive Officer Exxon Mobil Corporation 5959 Las Colinas Boulevard Irving, Texas 75039-2298 John R. Stafford Chairman, President and Chief Executive Officer American Home Products Corporation Five Giralda Farms Madison, New Jersey 07940 Lloyd D. Ward Former Chairman of the Board and Chief Executive Officer Maytag Corporation c/o J.P. Morgan Chase & Co. 270 Park Avenue New York, New York 10017-2070 -20- Douglas A. Warner III Chairman of the Board J.P. Morgan Chase & Co. 270 Park Avenue New York, New York 10017-2070 Marina v. N. Whitman Professor of Business Administration and Public Policy The University of Michigan School of Public Policy 411 Lorch Hall, 611 Tappan Street Ann Arbor, Michigan 48109-1220 -21- -----END PRIVACY-ENHANCED MESSAGE-----